Mazdutide
Overview
Mazdutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist delivered as a synthetic peptide. By co-activating both receptors, it aims to combine the glucose-lowering and weight-reducing effects of GLP-1 with the energy-expenditure and hepatic fat-reducing actions of glucagon receptor stimulation. This dual mechanism is hypothesized to provide enhanced metabolic benefits in obesity and metabolic dysfunction-associated steatotic liver disease.
Key Research Findings
Phase 2 studies in obesity have shown significant weight reduction and improvements in liver fat content compared to placebo. Data presented at international obesity and liver meetings in 2022 and 2023 support further development in metabolic indications. Phase 3 trials are in progress to confirm these findings in larger populations.
Subcutaneous injection
In Clinical Trials
Interested in Mazdutide?
Find a verified provider experienced with Mazdutide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Mazdutide ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.